Panacea Biotec has informed that the Company has instituted a suit before the Hon'ble Delhi High Court seeking to restrain Sanofi Healthcare India from marketing a fully liquid hexavalent vaccine that would infringe Company's patent for its fully liquid Whole Cell Pertussis based fully liquid Hexavalent Vaccine, EasySix. Panacea Biotec's EasySix is a first of its kind Whole Cell Pertussis based fully liquid Hexavalent Vaccine which comes in a pre-filled syringe and is used to vaccinate against, Diphtheria, Tetanus, Whooping Cough, Hepatitis B, Haemophilus influenza type b and Inactivated Polio (DTwP-HepB-Hib-IPV). EasySix has been in the market since 2017. A brief note in respect of the above-mentioned matter is enclosed for information and record.
The above information is a part of company’s filings submitted to BSE.
